Intervention

PF-07799933

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials2

Recruiting0

Common conditions15

Lead sponsors shown1

Clinical trials

2 shown

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid TumorsNCT05538130 · 2022-11-30

ACTIVE_NOT_RECRUITING

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.NCT05355701 · 2022-07-05

ACTIVE_NOT_RECRUITING

Common conditions

Glioma2 Melanoma2 Thyroid Cancer2 Advanced Colorectal Cancer (Part 1)1 Advanced or Metastatic Solid Tumors1 Brain Neoplasms1 Differentiated Thyroid Cancer1 HGG1 High Grade Glioma1 LGG1 Low Grade Glioma1 Malignant Neoplasms1 Non-Small Cell Lung Cancer1 Non-Small-Cell Lung Cancer1 NSCLC (Non-small Cell Lung Cancer)1

Leading sponsors

Pfizer 2

Trial status mix

ACTIVE_NOT_RECRUITING2

Phase mix

PHASE12

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.